

Joseph Mannello: Executive Profile & Biography - Bloomberg









































  





















































































July 26, 2017 9:39 AM ET
Personal Products

Company Overview of MYOS RENS Technology Inc.



SnapshotPeople 




OverviewBoard MembersCommittees



Executive Profile
Joseph   Mannello  Interim Chief Executive Officer and Director, MYOS RENS Technology Inc.AgeTotal Calculated CompensationThis person is connected to 1 Board Members in 1 different organizations across 3 different industries.See Board Relationships59$111,312As of Fiscal Year 2016
Background

		Mr. Joseph Mannello, also Known as Joe, has been Interim Chief Executive Officer of MYOS RENS Technology Inc. since September 1, 2016. Mr. Mannello served as a Consultant of MYOS RENS Technology Inc. since May 2015 until September 2016. Mr. Mannello has more than 27 years of experience in fixed income and financial services. He served as Executive Managing Director at Brean Capital, LLC since March 2013 until May 2015. Mr. Mannello served as Head of Corporate Credit ... and Executive Managing Director of Gleacher & Company, Inc., since March 2008 until March 2012. He served as the Head of Debt Capital Markets at Broadpoint Gleacher Securities Group, Inc. Mr. Mannello joined Gleacher & Company in 2008. He served as Executive Managing Director and Head of Corporate Credit Division at Gleacher & Company Securities, Inc. Mr. Mannello served as an Executive Managing Director and Head of Fixed Income Division of Broadpoint Securities Group, Inc. since January 2008. At BNY Capital Markets, Mr. Mannello served as the Head of Fixed Income and Managing Director from 1998 to 2008. Prior to BNY Capital Markets, he founded Mendham Capital. Mr. Mannello started his career with Printon Kane Group in 1981 and served as its Partner since 1984 and President since 1990. He has been Director of  MYOS RENS Technology Inc., since December 17, 2015. He served as an Independent Director of MYOS RENS Technology Inc. since December 17, 2015. Mr. Mannello graduated from Rutgers University in 1979.Read Full Background




Corporate Headquarters
45 Horsehill RoadCedar Knolls, New Jersey 07927United StatesPhone: 973-509-0444Fax: --
Board Members Memberships
2015-PresentInterim Chief Executive Officer and DirectorMYOS RENS Technology Inc.
Education
Unknown/Other Education 1979Rutgers, The State University of New Jersey
Other Affiliations
Brean Capital, LLCGleacher & Company, Inc.Gleacher & Company Securities, Inc.Rutgers, The State University of New Jersey


Annual Compensation
Salary$82,600Total Annual Compensation$82,600
Stocks Options
Restricted Stock Awards$12,631All Other Compensation$16,081
Total Compensation
Total Annual Cash Compensation$98,681Total Short Term Compensation$82,600Other Long Term Compensation$28,712Total Calculated Compensation$111,312




Request Profile Update
















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



COMPETITOR COMPENSATIONNamePosition/CompanyCompensationJames Robert B. Quincey President, CEO & DirectorThe Coca-Cola Company$923.6KMiles D. White Chairman of the Board & Chief Executive OfficerAbbott Laboratories$1.9MEmma  Walmsley Chief Executive Officer & DirectorGlaxoSmithKline plc--Siobhan  Talbot B.Comm, FCAGroup Managing Director and Executive DirectorGlanbia plc$1.8MRobert F. Moran Interim Chief Executive Officer and DirectorGNC Holdings, Inc.$865.0KCompensation as of Fiscal Year 2016.










Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact MYOS RENS Technology Inc., please visit .  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close




























	MYOS Appoints Joseph Mannello As Interim Chief Executive Officer













































Employer:
Login
Post Jobs


Job Seeker:
Login
Sign Up

























Search Life Sciences Jobs





Search Job Title Only












Radius:
Miles



Km80.5
















                 News | News By Subject | News by Disease |  
    News By Date | Search News



















Get Our FREEIndustry eNewsletter

email:


*
            
*
            



















 

 






MYOS (MYOS) Appoints Joseph Mannello As Interim Chief Executive Officer  











Tweet








9/8/2016 8:22:42 AM




  Life Sciences Jobs
 


  &bullet; Newest Jobs - Last 24 Hours


  &bullet; California Jobs


  &bullet; Massachusetts Jobs


  &bullet; New Jersey Jobs


  &bullet; Maryland Jobs


  &bullet; Washington Jobs


  View More Jobs


CEDAR KNOLLS, NJ--(Marketwired - September 07, 2016) -  Highlighted Links Re Muscle health website MYOS RENS Technology Inc. MYOS RENS Technology Inc. ("MYOS RENS" or the "Company") (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, announced the appointment of Joseph Mannello as its interim Chief Executive Officer, effective September 1, 2016, and the election of Victor Mandel to its board of directors (the "Board").

"The Company has the potential to become a truly transformative presence in the bionutrition and biotherapeutics markets," Mr. Mannello stated. "The Company's management team and the Board are fully committed to achieving this goal, and I look forward to bringing my experience, leadership, and unique perspective to the Company as its interim chief executive officer." 

Mr. Mannello has served as a member of the Board since December 2015 and as an independent management consultant since May 2015. He previously served as Executive Managing Director and a member of the Operating Committee of Brean Capital LLC and as Executive Managing Director and as the Head of Corporate Credit of Gleacher & Company, Inc. Mr. Mannello served as a Managing Director and the Head of the Corporate Fixed Income Division of BNY Capital Markets, Inc., and founded and served as the Chief Executive Officer of Mendham Capital Group, Inc. Mr. Mannello received a BA in Psychology from Rutgers University. 

MYOS RENS also announced the election of Victor Mandel to the Board, filling a vacancy resulting from the recent resignation of Guiying Zhao. Mr. Mandel served as a director of MYOS RENS from December 2015 until March 2016. He is the founding partner of Criterion Capital Management, LLC and has over twenty-five years of experience in investments, corporate strategy and corporate governance. Mr. Mandel previously served as Co-Chairman of Ambac Financial Group, Inc. from May 2013 through December 2014 and as a director, chair of its Governance and Nominating Committee and member of its Audit and Strategy and Risk Policy Committees from May 2013 until May 2016. Additionally, he has previously served as a member of the board of directors and on the audit committees of Comsys IT Partners, Inc. (now a Manpower company), Broadpoint Gleacher Securities Group, Inc. (now Gleacher & Co., Inc.), and XLHealth Corp. (now a United Healthcare company). He previously served as the Chief Financial Officer of Circle.com and served as Executive Vice President, Finance and Development of Snyder Communications, Inc. from 1999 to 2000. From 1991 to 1999, Mr. Mandel served as vice president in the Investment Research department at Goldman Sachs & Co. Mr. Mandel holds an MBA in Finance from the Wharton School of Business at the University of Pennsylvania, an A.B. in Computer Science from Harvard University, and is a Chartered Financial Analyst.

About MYOS RENS Technology Inc. 
MYOS RENS is an emerging biotherapeutics and bionutrition company focused on the discovery, development, and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases. MYOS RENS is the owner of Fortetropin®, the first clinically-proven, all natural myostatin-reducing agent. Myostatin is a naturally-occurring regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing, as well as treating sarcopenia, a condition of age-related loss of muscle mass.  

To discover why MYOS RENS is known as "The Muscle Company™," visit www.myosrens.com.

Forward-Looking Statements 
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of Fortetropin® and its effects on myostatin inhibition, inflammatory cytokine levels and cholesterol levels, customer demand for our Rē Muscle Health™ and other products, market acceptance of our existing and future products in countries outside of the United States (such as Canada and China), the ability to create new products through research and development, growth in our revenue, the successful entry into new markets including the age management market, the ability to collect our accounts receivable from our distributors, our ability to raise capital to fund continuing operations, the ability to increase shareholder value, the ability to generate revenue and cash flow from sales of Fortetropin® and Rē Muscle Health™ products, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the ability to maintain and expand our manufacturing capabilities and reduce the costs of our products, the ability to comply with NASDAQ's continuing listing standards, competition from other providers and products, risks in product development, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law. 

These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease. 




Company Contact Joseph MannelloCEOMYOS RENS Technology Inc.Email Contact(973) 509-0444 Investor Relations ContactMichael BriolaCEOMotion Communications, Inc.Email Contact(972) 646-3400 








                Read at
                BioSpace.com







Related News
MYOS (MYOS) Reports Positive Results From Fortetropin Clinical Study   Why Mylan (MYL)’s CEO Remains One Of Fortune's Most Powerful Women  MYOS (MYOS) Announces Corporate Name Change To MYOS RENS Technology Inc. How Merck & Co. (MRK)'s CIO Is Quietly Changing The Tech-Startup World  MYOS (MYOS) Announces The Initial Closing Of A Strategic Investment By RENS Technology Inc. Is There Anyone The Drug Industry Hates More Than This AIDS Activist?  MYOS (MYOS) Announces Election Of New Directors And Appointment Of Ren Ren As Global Chairman   Five-Figure Salaries. Big Hair. Pharma, 1987  MYOS (MYOS) Announces Strategic Investment By RENS Technology Inc. KaloBios (KBIO), Post-Shkreli, Vows 'Maniacal' Focus On R&D And Transparency  




Please enable JavaScript to view the comments powered by Disqus.
comments powered by Disqus






















                            •
                            BioSpace.com










                            •
                            MYOS 




             
        





                            •
                            Biotech/Pharma - Personnel




             
        















                              
                            

                              
                             
                              
                            

                              
                            








                 





























    Joseph Mannello | MYOS RENS Technology Inc | ZoomInfo.comMYOS RENS Technology Inc. Appoints Joseph Mannello as Interim Chief Executive OfficerHomeMailFlickrTumblrNewsSportsFinanceCelebrityAnswersGroupsMobileMoreTry Yahoo Finance on Firefox »YahooSearchSearchSign inU.S. Markets close in 6 hrs 21 minsS&P 5002,480.00+2.87 (+0.12%)Dow 3021,718.95+105.52 (+0.49%)Nasdaq6,428.77+16.60 (+0.26%)MYOS RENS Technology Inc. Appoints Joseph Mannello as Interim Chief Executive OfficerMarketwiredSeptember 7, 2016ReblogShareTweetShareCEDAR KNOLLS, NJ--(Marketwired - Sep 7, 2016) -  MYOS RENS Technology Inc. ("MYOS RENS" or the "Company") (  NASDAQ :  MYOS ), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, announced the appointment of Joseph Mannello as its interim Chief Executive Officer, effective September 1, 2016, and the election of Victor Mandel to its board of directors (the "Board")."The Company has the potential to become a truly transformative presence in the bionutrition and biotherapeutics markets," Mr. Mannello stated. "The Company's management team and the Board are fully committed to achieving this goal, and I look forward to bringing my experience, leadership, and unique perspective to the Company as its interim chief executive officer."Mr. Mannello has served as a member of the Board since December 2015 and as an independent management consultant since May 2015. He previously served as Executive Managing Director and a member of the Operating Committee of Brean Capital LLC and as Executive Managing Director and as the Head of Corporate Credit of Gleacher & Company, Inc. Mr. Mannello served as a Managing Director and the Head of the Corporate Fixed Income Division of BNY Capital Markets, Inc., and founded and served as the Chief Executive Officer of Mendham Capital Group, Inc. Mr. Mannello received a BA in Psychology from Rutgers University. MYOS RENS also announced the election of Victor Mandel to the Board, filling a vacancy resulting from the recent resignation of Guiying Zhao. Mr. Mandel served as a director of MYOS RENS from December 2015 until March 2016. He is the founding partner of Criterion Capital Management, LLC and has over twenty-five years of experience in investments, corporate strategy and corporate governance. Mr. Mandel previously served as Co-Chairman of Ambac Financial Group, Inc. from May 2013 through December 2014 and as a director, chair of its Governance and Nominating Committee and member of its Audit and Strategy and Risk Policy Committees from May 2013 until May 2016. Additionally, he has previously served as a member of the board of directors and on the audit committees of Comsys IT Partners, Inc. (now a Manpower company), Broadpoint Gleacher Securities Group, Inc. (now Gleacher & Co., Inc.), and XLHealth Corp. (now a United Healthcare company). He previously served as the Chief Financial Officer of Circle.com and served as Executive Vice President, Finance and Development of Snyder Communications, Inc. from 1999 to 2000. From 1991 to 1999, Mr. Mandel served as vice president in the Investment Research department at Goldman Sachs & Co. Mr. Mandel holds an MBA in Finance from the Wharton School of Business at the University of Pennsylvania, an A.B. in Computer Science from Harvard University, and is a Chartered Financial Analyst.About MYOS RENS Technology Inc.  MYOS RENS is an emerging biotherapeutics and bionutrition company focused on the discovery, development, and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases. MYOS RENS is the owner of Fortetropin®, the first clinically-proven, all natural myostatin-reducing agent. Myostatin is a naturally-occurring regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing, as well as treating sarcopenia, a condition of age-related loss of muscle mass. To discover why MYOS RENS is known as "The Muscle Company™," visit www.myosrens.com.Forward-Looking Statements  Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of Fortetropin® and its effects on myostatin inhibition, inflammatory cytokine levels and cholesterol levels, customer demand for our Rē Muscle Health™ and other products, market acceptance of our existing and future products in countries outside of the United States (such as Canada and China), the ability to create new products through research and development, growth in our revenue, the successful entry into new markets including the age management market, the ability to collect our accounts receivable from our distributors, our ability to raise capital to fund continuing operations, the ability to increase shareholder value, the ability to generate revenue and cash flow from sales of Fortetropin® and Rē Muscle Health™ products, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the ability to maintain and expand our manufacturing capabilities and reduce the costs of our products, the ability to comply with NASDAQ's continuing listing standards, competition from other providers and products, risks in product development, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextPhil Mickelson trash-talked Jordan Spieth at the Open Championship — and Phil is going to have to eat his wordsBusiness InsiderEngineer Finds Pattern; Makes Millions in StocksMoney MorningSponsoredHere's Trump's approval rating in every stateBusiness InsiderSenate opens 'Obamacare' debate at last but outcome in doubtAssociated PressEconomists answer, are we at full employment?Yahoo Finance VideoA Penny-Crypto Miracle Making Some Americans RichAgora FinancialSponsoredStocks rise as the earnings parade marches on and investors wait for the FedYahoo FinanceDonald Trump thinks Jeff Bezos is his biggest threatYahoo FinanceMotorola's Moto Z2 Force is a smartphone guaranteed not to shatterYahoo FinanceStart Earning Miles With The Best Travel CardWise BreadSponsoredFix My Finances: I borrowed from my 401(k)Yahoo FinanceFormer Obama official weighs in on Trump's plan to bring back manufacturing jobsYahoo Finance VideoWhy Barnes & Noble still has value for the right buyerYahoo FinanceSimple At-Home Fix Fights Almost ALL Skin IssuesGundry MDSponsoredTRUMP: Sessions only endorsed me because of my crowd sizesBusiness InsiderConservative media outlets are sending Trump a big warning on Jeff Sessions — and Trump is paying attentionBusiness InsiderBoy Scouts defend inviting Trump amid backlash over president’s rambling speechliberaltroll10: Trump goes to the Boy Scouts and makes EVERYTHING ABOUT HIM.  Nice huh?Join the Conversation1 / 53.8k











 






Management Team :: MYOS RENS Technology Inc. (MYOS)












  





































  OUR PARTNERS
  CONTACT US





















Menu






 




Management Team

















Overview


Analyst Coverage


News / Events


Press Releases


IR Calendar


Email Alerts


Videos




Company Information


Profile


Management Team


Presentations


IR Contacts


FAQ




Financial Information


Financials


Quarterly Results




Stock Data


Quote


Charts


Historical Data




SEC Filings


All SEC Filings


Annual Reports


Quarterly Reports


Section 16 Filings




Corporate Governance


Board of Directors


Governance Docs







Email Alerts
Tear Sheet
IR Contacts
RSS News Feed
















Joseph Mannello
Director, Interim CEO


Joseph Mannello has served as a consultant since May 2015. From March 2013 to May 2015, he served as the executive managing director at Brean Capital LLC, an independent investment bank and asset management firm, where he also served as a member of the firm’s operating committee. From March 2008 to March 2012, Mr. Mannello was the head of corporate credit for Gleacher & Company, Inc. (OTC:GLCH), a publicly-traded investment bank. Prior to that, he was the head of the fixed income division of BNY Capital Markets, Inc., a subsidiary of The Bank of New York Mellon Corp. (NYSE:BK). We believe Mr. Manello’s extensive financial markets background qualifies him to serve on our Board of Directors. 





Joseph DiPietro
Controller


Joseph DiPietro joined Myos in September 2016. Mr. DiPietro was most recently the CFO at the Harlem School of the Arts in New York. He graduated St. John’s University in 1988 with a BS in Accounting. He obtained his CPA license while working as an auditor for McGladrey (RSM). He has held positions such as VP Finance, Controller, and Director of Financial Reporting at a few public companies such as Pfizer, Celgene, Juno Online, Majesco, Audible and Turtle Beach. 





Maghsoud Dariani
Science & Technology


Maghsoud Dariani has over 30 years of diverse and progressive management experience in the development and commercialization of products in the pharmaceutical industry. Mr. Dariani has a successful record of business management, strategic planning, acquisition and divestiture, project management, production management, R&D management, economic evaluations, competitor analyses, and development and administration of multi-million dollar budgets. Mr. Dariani is also an entrepreneurial business leader with a sound grasp of successful business strategies, with an excellent foundation in science and engineering, and a strong background in product development and commercialization.   As President & CEO of Semorex Inc. – a privately held company focused on the discovery and development of novel therapeutics for cancer, Mr. Dariani is responsible for overall management of the business and R&D, as well as securing capital for operations.  Prior to joining Semorex, Mr. Dariani was President of Focus Pharmaceuticals, Inc., where he managed the development and approval of drug products, achieving one FDA approval and bringing another to the clinical evaluation stage then successfully negotiated the sale of the company in February 2003.  Prior to Focus, Mr. Dariani was Vice President of the chiral pharmaceutical business unit at Celgene Corporation.  During his twelve years at Celgene, Mr. Dariani developed and implemented Celgene’s manufacturing strategy, managed and successfully sold Celgene’s chiral intermediates business unit, and formulated a strategic plan for leveraging Celgene’s expertise in chiral technologies towards the development of chirally pure drug products.  Mr. Dariani was responsible for the successful development and FDA approval of the chirally pure versions of Ritalin, which are currently marketed by Novartis under the Focalin and Focalin XR trade names. Prior to Celgene, Mr. Dariani held progressively more responsible engineering and development positions at Celanese Corporation.  Mr. Dariani holds a BS degree from The City College of NY and a MS degree from University of Massachusetts in Chemical Engineering.  Mr. Dariani is a member of Board of Directors at Semorex Inc. and Mesa Therapeutics. 





Dominick Commesso
Executive VP of Sales and Marketing


Dominick Commesso joined Myos in February, 2016 to spearhead sales and marketing.  Mr. Commesso is joining Myos after a very successful  23-year career on Wall Street as an equity sales trader, working on many different institutional size platforms from Credit Suisse to Alex Brown. He brings his well diversified wall street skill set and deep client relationships to MYOS corp.  Mr. Commesso is a lifetime athlete who played soccer at the Division 1 college level for University of North Carolina at Charlotte and has coached at the youth level up to High School. His Passion for health, fitness and financial background will help drive global sales and challenge the team every day to be better.   





Neerav Dilip Padliya, PhD, PMP
Vice President, Research Alliances


Neerav Dilip Padliya, PhD, PMP is Vice President, Research Alliances at MYOS RENS Technology Inc. His career success began in 2006 at Celgene Corporation where he was the Principal Investigator behind a highly interdisciplinary program focused on mass spectrometry-based proteomic studies of placenta-derived populations of stem cells and natural killer cells. Dr. Padliya spearheaded collaborations with Immunologists and Cell Biologists that led to the issue of two U.S. patents, one pending U.S. patent application and the publication of one journal article as senior author. In 2011, Dr. Padliya joined AB SCIEX, (a wholly owned operating company of Danaher Corporation) a premier manufacturer of high-end mass spectrometry instrumentation used for applications in pharmaceuticals, clinical laboratories, environmental monitoring and the food and beverage industry. Prior to joining MYOS RENS Technology Inc., Dr. Padliya worked closely with the North American Sales Force at AB SCIEX to perform several winning demonstrations of accurate mass, high-resolution mass spectrometers that paved the way for new business opportunities with major pharmaceutical and biotechnology accounts. Dr. Padliya graduated with a B.Sc. (Honors), Chemistry in 2001 from McMaster University (Canada) and graduated with a PhD in Analytical Chemistry in 2005 from the State University of New York at Buffalo (USA). Dr. Padliya is the author of five peer-reviewed publications as first author and an inventor on two U.S. patents and one pending U.S. patent application. Dr. Padliya has served as a reviewer for well-reputed journals such as Anal. Chimica Acta, Anal. Methods, Integrative Biology, and Molecular Biosystems. 





Joanne Goodford
Operations, Facility Development Manager, Special Projects


Ms. Goodford has more than 25 years of management experience, with six years in project operations during contract start-up phases on government initiatives in a healthcare setting.  Her role included office facilities build-outs, floor plan development, quality assurance, establishing processes and workflows, recruiting, hiring and training of staff.  Ms. Goodford also served on several proposal development teams which had a 100% win rate and included responding to a $350m contract for the state of Georgia.
With an eye to quality outcomes, timely project completion and cost management, Ms. Goodford served as Project Manager for the build-out of MYOS RENS’ corporate offices bringing the project in under budget and under deadline.  Ms. Goodford holds a BS from Montclair State University. 





Alexander Tess
Quality Assurance Manager


Mr. Tess is responsible for implementing and maintaining the effectiveness of the quality system at MYOS RENS Technology Inc. He successfully runs programs that ensure all specifications for products or services are met and monitors progress and compliance through regular inspections. Mr. Tess develops standard operating procedures and manages stability studies, ensuring compliance with protocols. Prior to joining MYOS RENS Technology Inc., Mr. Tess worked as a research associate at Celgene Cellular Therapeutics exploring platforms for cell-based therapies in the therapeutic areas of cancer and inflammatory diseases. He excelled in establishing methods for differentiation of various cell lines form mesenchymal stem cells as well as characterizing and monitoring cell lines for comprehensive in vitro studies. Mr. Tess has a BS in Biochemistry from Fairleigh Dickinson University as well as a BS degree from Kazan Aviation University in Aircraft Engineering. In addition, Mr. Tess has completed Pharmaceutical Quality Assurance and Control Trainings. 






















































Joseph Mannello | MYOS RENS Technology Inc. | Email, interim CEO, @myosrens.com 











































LOGIN

7 DAY FREE TRIAL


























Joseph Mannello

 MYOS RENS Technology Inc.  interim CEO


Updated On : 
                    Apr 19, 2017                            

export












Email Address: Email not Avail
                                        


45 Horsehill Road

Cedar Knolls, NJ 07927


Email format for @myosrens.com

Direct Phone: Not Available 









Type:

                    Private                
Employees: 
50 - 99

Revenue:  
Not Available

Industry:  
                        Biotech/Healthcare->BioTech/Drugs                    
SIC Code:  
                         2836  - Biological Products, Except Diagnostic








 BIOGRAPHY

 
                    Joseph Mannello is part of MYOS RENS Technology Inc., an organization which has its main offices in Cedar Knolls, NJ.  Joseph serves as the interim CEO at MYOS RENS Technology Inc..  If you're searching for MYOS RENS Technology Inc. email addresses, you can also find those on their Lead411 profile with the domain @myosrens.com along with Joseph Mannello's linkedin name, twitter tweets, wiki, phone numbers, and biography.MYOS RENS Technology Inc.'s Lead411 profile is categorized under the Biotech/drugs industry.  Some possible email formats for Joseph Mannello are JMannello@myosrens.com, Joseph.Mannello@myosrens.com, Joseph@myosrens.com, and Joseph_Mannello@myosrens.com. If you sign up for our free trial you will see our email@myosrens.com addresses.            


Similar People:
Joseph M - Pro Services
Their Recruitment Consultant is Joseph M. Their Lead411 profile is categorized under the Technology consulting/services industry. If you're checking for Adronics, Inc. email addresses, these are also available on Lead411 with the @ai-us.com email addresses and possibly Joseph M's email. Adronics, Inc. is based in Plano, TX. You can also get Joseph M's linkedin info, twitter data, phone numbers, wiki and biography on their Lead411 profile. Their contact information is filed under the Technology consulting/services category.  Some possible email formats for Joseph M are JM@ai-us.com, Joseph.M@ai-us.com, Joseph@ai-us.com, and Joseph_M@ai-us.com. If you sign up for our free trial you will see our email@ai-us.com addresses.
Joseph M - Executive
Have you been looking for contact information, like phone numbers and emails, on Joseph M?  Lead411 provides data on him which include twitter, linkedin url, wiki, and biography.  There is also Ecolab Inc. email addresses within the @ecolab.com profile so Joseph M's email could be included.  Joseph M is part of the Ecolab Inc. which has its main offices in St. Paul, MN.  Currently holds the post of Vice President Marketing.  You can find the company data on Lead411 under the Personal/household products industry.  Some possible email formats for Joseph M are JM@ecolab.com, Joseph.M@ecolab.com, Joseph@ecolab.com, and Joseph_M@ecolab.com. If you sign up for our free trial you will see our email@ecolab.com addresses.
Joseph M - Pro Services
Joseph M is part of Benilde-St. Margaret's School, an organization which has its main offices in St. Louis Park, MN.  Joseph serves as the Teacher at Benilde-St. Margaret's School.  If you're searching for Benilde-St. Margaret's School email addresses, you can also find those on their Lead411 profile with the domain @bsmschool.org along with Joseph M's linkedin name, twitter tweets, wiki, phone numbers, and biography.Benilde-St. Margaret's School's Lead411 profile is categorized under the Schools industry.  Some possible email formats for Joseph M are JM@bsmschool.org, Joseph.M@bsmschool.org, Joseph@bsmschool.org, and Joseph_M@bsmschool.org. If you sign up for our free trial you will see our email@bsmschool.org addresses.


People Directory > Joseph Mannello

















 






Press Releases :: MYOS RENS Technology Inc. (MYOS)












  





































  OUR PARTNERS
  CONTACT US





















Menu






 




Press Releases

















Overview


Analyst Coverage


News / Events


Press Releases


IR Calendar


Email Alerts


Videos




Company Information


Profile


Management Team


Presentations


IR Contacts


FAQ




Financial Information


Financials


Quarterly Results




Stock Data


Quote


Charts


Historical Data




SEC Filings


All SEC Filings


Annual Reports


Quarterly Reports


Section 16 Filings




Corporate Governance


Board of Directors


Governance Docs







Email Alerts
Tear Sheet
IR Contacts
RSS News Feed










MYOS RENS Technology Inc. Appoints Joseph Mannello as Interim Chief Executive Officer
Download PDF

Company Also Announces Election of Victor Mandel to Board of Directors
CEDAR KNOLLS, NJ -- (Marketwired) -- 09/07/16 -- 
 MYOS RENS Technology Inc. ("MYOS RENS" or the "Company") (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, announced the appointment of Joseph Mannello as its interim Chief Executive Officer, effective September 1, 2016, and the election of Victor Mandel to its board of directors (the "Board").
"The Company has the potential to become a truly transformative presence in the bionutrition and biotherapeutics markets," Mr. Mannello stated. "The Company's management team and the Board are fully committed to achieving this goal, and I look forward to bringing my experience, leadership, and unique perspective to the Company as its interim chief executive officer." 
Mr. Mannello has served as a member of the Board since December 2015 and as an independent management consultant since May 2015. He previously served as Executive Managing Director and a member of the Operating Committee of Brean Capital LLC and as Executive Managing Director and as the Head of Corporate Credit of Gleacher & Company, Inc. Mr. Mannello served as a Managing Director and the Head of the Corporate Fixed Income Division of BNY Capital Markets, Inc., and founded and served as the Chief Executive Officer of Mendham Capital Group, Inc. Mr. Mannello received a BA in Psychology from Rutgers University. 
MYOS RENS also announced the election of Victor Mandel to the Board, filling a vacancy resulting from the recent resignation of Guiying Zhao. Mr. Mandel served as a director of MYOS RENS from December 2015 until March 2016. He is the founding partner of Criterion Capital Management, LLC and has over twenty-five years of experience in investments, corporate strategy and corporate governance. Mr. Mandel previously served as Co-Chairman of Ambac Financial Group, Inc. from May 2013 through December 2014 and as a director, chair of its Governance and Nominating Committee and member of its Audit and Strategy and Risk Policy Committees from May 2013 until May 2016. Additionally, he has previously served as a member of the board of directors and on the audit committees of Comsys IT Partners, Inc. (now a Manpower company), Broadpoint Gleacher Securities Group, Inc. (now Gleacher & Co., Inc.), and XLHealth Corp. (now a United Healthcare company). He previously served as the Chief Financial Officer of Circle.com and served as Executive Vice President, Finance and Development of Snyder Communications, Inc. from 1999 to 2000. From 1991 to 1999, Mr. Mandel served as vice president in the Investment Research department at Goldman Sachs & Co. Mr. Mandel holds an MBA in Finance from the Wharton School of Business at the University of Pennsylvania, an A.B. in Computer Science from Harvard University, and is a Chartered Financial Analyst.
About MYOS RENS Technology Inc. 
        MYOS RENS is an emerging biotherapeutics and bionutrition company focused on the discovery, development, and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases. MYOS RENS is the owner of Fortetropin®, the first clinically-proven, all natural myostatin-reducing agent. Myostatin is a naturally-occurring regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing, as well as treating sarcopenia, a condition of age-related loss of muscle mass.  
To discover why MYOS RENS is known as "The Muscle Company™," visit www.myosrens.com.
Forward-Looking Statements 
        Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of Fortetropin® and its effects on myostatin inhibition, inflammatory cytokine levels and cholesterol levels, customer demand for our Rē Muscle Health™ and other products, market acceptance of our existing and future products in countries outside of the United States (such as Canada and China), the ability to create new products through research and development, growth in our revenue, the successful entry into new markets including the age management market, the ability to collect our accounts receivable from our distributors, our ability to raise capital to fund continuing operations, the ability to increase shareholder value, the ability to generate revenue and cash flow from sales of Fortetropin® and Rē Muscle Health™ products, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the ability to maintain and expand our manufacturing capabilities and reduce the costs of our products, the ability to comply with NASDAQ's continuing listing standards, competition from other providers and products, risks in product development, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law. 
These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease. 

Company Contact 
Joseph Mannello
CEO
MYOS RENS Technology Inc.
Email Contact
(973) 509-0444 

Investor Relations Contact
Michael Briola
CEO
Motion Communications, Inc.
Email Contact
(972) 646-3400

Source: MYOS RENS Technology Inc.

Released September 7, 2016













































MYOS RENS Technology Inc. Appoints Joseph Mannello as Interim Chief Executive Officer - MarketWatch

















































X

Tweet
 

Share this bulletin

Get news bulletins by email

Bulletin

Dow and Nasdaq hit all-time highs at Wednesday opening bell »
        




Investor Alert







New York Markets Close in:



Market Snapshot
Winners and Losers




















press release


					Sept. 7, 2016, 12:35 p.m. EDT
				
MYOS RENS Technology Inc. Appoints Joseph Mannello as Interim Chief Executive Officer
























CEDAR KNOLLS, NJ, Sep 07, 2016 (Marketwired via COMTEX) --
Company Also Announces Election of Victor Mandel to Board of Directors


                                        








CEDAR KNOLLS, NJ--(Marketwired - Sep 7, 2016) -  MYOS RENS Technology Inc. ("MYOS RENS" or the "Company")                 

/quotes/zigman/68495277/composite MYOS
0.00%


, an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, announced the appointment of Joseph Mannello as its interim Chief Executive Officer, effective September 1, 2016, and the election of Victor Mandel to its board of directors (the "Board").


                                        








"The Company has the potential to become a truly transformative presence in the bionutrition and biotherapeutics markets," Mr. Mannello stated. "The Company's management team and the Board are fully committed to achieving this goal, and I look forward to bringing my experience, leadership, and unique perspective to the Company as its interim chief executive officer."


                                        








Mr. Mannello has served as a member of the Board since December 2015 and as an independent management consultant since May 2015. He previously served as Executive Managing Director and a member of the Operating Committee of Brean Capital LLC and as Executive Managing Director and as the Head of Corporate Credit of Gleacher & Company, Inc. Mr. Mannello served as a Managing Director and the Head of the Corporate Fixed Income Division of BNY Capital Markets, Inc., and founded and served as the Chief Executive Officer of Mendham Capital Group, Inc. Mr. Mannello received a BA in Psychology from Rutgers University. 


                                        








MYOS RENS also announced the election of Victor Mandel to the Board, filling a vacancy resulting from the recent resignation of Guiying Zhao. Mr. Mandel served as a director of MYOS RENS from December 2015 until March 2016. He is the founding partner of Criterion Capital Management, LLC and has over twenty-five years of experience in investments, corporate strategy and corporate governance. Mr. Mandel previously served as Co-Chairman of Ambac Financial Group, Inc. from May 2013 through December 2014 and as a director, chair of its Governance and Nominating Committee and member of its Audit and Strategy and Risk Policy Committees from May 2013 until May 2016. Additionally, he has previously served as a member of the board of directors and on the audit committees of Comsys IT Partners, Inc. (now a Manpower company), Broadpoint Gleacher Securities Group, Inc. (now Gleacher & Co., Inc.), and XLHealth Corp. (now a United Healthcare company). He previously served as the Chief Financial Officer of Circle.com and served as Executive Vice President, Finance and Development of Snyder Communications, Inc. from 1999 to 2000. From 1991 to 1999, Mr. Mandel served as vice president in the Investment Research department at Goldman Sachs & Co. Mr. Mandel holds an MBA in Finance from the Wharton School of Business at the University of Pennsylvania, an A.B. in Computer Science from Harvard University, and is a Chartered Financial Analyst.


                                        








About MYOS RENS Technology Inc. 

        MYOS RENS is an emerging biotherapeutics and bionutrition company focused on the discovery, development, and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases. MYOS RENS is the owner of Fortetropin®, the first clinically-proven, all natural myostatin-reducing agent. Myostatin is a naturally-occurring regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing, as well as treating sarcopenia, a condition of age-related loss of muscle mass. 


                                        








To discover why MYOS RENS is known as "The Muscle Company™," visit         www.myosrens.com
.


                                        








Forward-Looking Statements 

        Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of Fortetropin® and its effects on myostatin inhibition, inflammatory cytokine levels and cholesterol levels, customer demand for our Rē Muscle Health™ and other products, market acceptance of our existing and future products in countries outside of the United States (such as Canada and China), the ability to create new products through research and development, growth in our revenue, the successful entry into new markets including the age management market, the ability to collect our accounts receivable from our distributors, our ability to raise capital to fund continuing operations, the ability to increase shareholder value, the ability to generate revenue and cash flow from sales of Fortetropin® and Rē Muscle Health™ products, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the ability to maintain and expand our manufacturing capabilities and reduce the costs of our products, the ability to comply with NASDAQ's continuing listing standards, competition from other providers and products, risks in product development, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.


                                        








These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.


                                        








Company Contact 

Joseph Mannello

CEO

MYOS RENS Technology Inc.

Email Contact

(973) 509-0444 



Investor Relations Contact

Michael Briola

CEO

Motion Communications, Inc.

Email Contact

(972) 646-3400


                                        








� 2016 Nasdaq, Inc.  All rights reserved.
                    



/quotes/zigman/68495277/composite 





 Add to watchlist
                    
MYOS




MYOS RENS Technology Inc.


                US
                
                    : U.S.: Nasdaq
                
            




$
1.75



0.00
0.00%




Volume: 416.00
July 26, 2017 9:35a






P/E RatioN/A
Dividend YieldN/A




Market Cap$10.23 million
Rev. per Employee$31,333





 









 





































Most Popular





1.





Commodities Corner

Here’s why oil just scored its biggest one-day rally of 2017






2.





MarketWatch First Take

AMD earnings give investors what they wanted — now it must deliver on servers






3.






Don’t have a college degree? These are the industries with the best-paid jobs






4.






If you can buy only one stock or ETF, make it this one






5.





Clip from the News Hub - GMT

Christopher Nolan’s ‘Dunkirk’: 'Virtual Reality Without the Headset'








Find a Broker

Partner Center »























Featured Stories





Seeing America again through new eyes







How to dig yourself out of debt







Move over, Tesla? Karma unveils its hybrid sports car







The salary you need to afford a home in these 25 cities







Why OPEC will never cut production again













Log In




9:39 AM EDT
July 26, 2017


/marketstate/country/us
New York

	Open


/marketstate/country/uk
London

	Open


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
9:38aThe allure of ‘damaged’ stocks as tech mania goes wild
9:34aMcDonald's price target raised to $170 from $145 at Canaccord Genuity
9:33aU.S. stocks open higher, hit records on round of strong corporate results
9:32aNasdaq Composite Index opens higher by 0.2%
9:32aDow Jones Industrial Average advances past intraday record high
9:31aS&P 500 opens higher by 0.1%
9:31aBoeing's stock soars 5.3% to record high in morning trade
9:30aStocks open higher; Boeing helps push Dow to record
9:28aMcDonald's stock price target raised to $176 from $172 at Instinet
9:28aCitigroup stock price target raised to $81 from $78 at Instinet
9:28aTexas Instruments stock price target raised to $80 from $75 at Instinet
9:27aA.O. Smith stock price target raised to $60 from $58 at Boenning & Scattergood
9:24aCORRECTEDState National to be acquired by Markel in deal valuing the insurer at nearly $890 million
9:23aFord shares are down 1.7% after Q2 earnings
9:22aDiana Containerships' stock plummets after plans for second reverse stock split in a month
9:21aShares of Verizon Communications are up more than 2%
9:19aShares of Dish Network are down 2.6% premarket
9:17aHealth-care fund managers say a spike in drugs and devices will produce big returns
9:15aDollar steadies as investors await Fed’s policy signals
9:13aA money manager fights the social pressure for ‘more house’
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,717.87

+104.44
+0.48%





nasdaq

/quotes/zigman/12633936/realtime
6,428.49

+16.31
+0.25%





s&p 500

/quotes/zigman/3870025/realtime
2,480.03

+2.90
+0.12%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15






































































Joseph Mannello | MYOS RENS Technology Inc. | Email CEO @myosrens.com CFO 

















































LOGIN

7 DAY FREE TRIAL






















































 




                    MYOS RENS Technology Inc.





myosrens.com





45 Horsehill Road                 
                 
Cedar Knolls, NJ 07927
Phone: 973-509-0444
Fax: N/A









 














Type:

                    Private                
Employees:

50 - 99

Revenue: 

Not Available

Industry:  
                    Biotech/Healthcare->BioTech/Drugs                
SIC Code:  
                     2836  - Biological Products, Except Diagnostic
















View:




Employees



IT Intelligence



News



Currently Hiring




Historical Trends









 IT INTELLIGENCE











No Categories





No Products Found












Helpful Hint
The Inside View displays a list of technologies and products used internally at a company




                        F
                        i
                        r
                        e
                        w
                        a
                        l
                        l
                  








Show All Analytics
AudioVideo
CDN
CMS
OS










Google Analytics
Google Analytics shows you the full customer picture across ads and videos, websites and social tools, tablets and smartphones. That makes it easier to serve your current customers and win new ones.






YouTube
YouTube is a video-sharing website, created by three former PayPal employees in February 2005 and owned by Google since late 2006, on which users can upload, view and share videos. 






Amazon AWS / Cloudfront
Amazon CloudFront is a content delivery web service.



Sign up to see all













Helpful Hint
The Outside View displays all the technologies and devices which can be seen on the Internet





 NEWS AND BACKGROUND
 NEWS AND BACKGROUND








Company in the News



                                            April 19, 2017 - New Contract
CustomerKansas State UniversityAmountUndisclosedLengthUndisclosedOtherStudy Impact Of Fortetropin On Reducing Muscle Loss In Dogs After Joint Surgery
Read Entire Article



 Sign up to see all press events 









Background

                                       Full company description is available with the free trial.            


















Name 
Email Address
Department 
Get Data











                                        Neerav Padliya                                    

Title: Vice President, Analytical Development







                         No Email Avail                            
Research & Development

export









                                        Joseph Mannello                                    

Title: interim CEO







                         No Email Avail                            
Executive

export









                                        Dominick Commesso                                    

Title: EVP Sales/Marketing







                         No Email Avail                            
Sales - Marketing

export









                                        Joanne Goodford                                    

Title: Operations, Facility Development Manager, Special Projects







                         No Email Avail                            
Operations

export









                                        Alexander Tess                                    

Title: Quality Assurance Manager







                         No Email Avail                            
Technology

export









                                        Joseph Dipietro                                    

Title: Controller







                         No Email Avail                            
Finance

export









                                        Maghsoud Dariani                                    

Title: Science & Technology







                         No Email Avail                            
Technology

export








Showing 1 to 
                7                                

                                    of 7 entries            









 LEVEL AND ORGANIZATION
 LEVEL AND ORGANIZATION












 HISTORICAL TRENDS
 HISTORICAL TRENDS

















Yearly


Quarterly




































Weekly


Quarterly









































 
Poll Question
Date Created
Current Result
Votes








Only for logged in user.




Additional Info:
MYOS RENS Technology Inc., is in the Biotech/drugs industry. Their main office can be found in Cedar Knolls, NJ, and they can be contacted through MYOS RENS Technology Inc. email using the domain @myosrens.com format, some important contact information like linkedin data, phone numbers, contacts for cfos, etc of which can be found on their Lead411 profile.  If you sign up for our free trial you will see our email@myosrens.com addresses.


Company Background:
Full company description is available with the free trial.


Ceo Reference:
Joseph Mannello
Trying to find Joseph Mannello's email, wiki, phone numbers, twitter, biography, and linkedin data?  You can check out MYOS RENS Technology Inc.'s profile on Lead411, where you can also get @myosrens.com contact information.  MYOS RENS Technology Inc. is an organization centered in Cedar Knolls, NJ, which you can find on Lead411 under the Biotech/drugs category.  Joseph Mannello is their interim CEO.  Some possible email formats for Joseph Mannello are JMannello@myosrens.com, Joseph.Mannello@myosrens.com, Joseph@myosrens.com, and Joseph_Mannello@myosrens.com. If you sign up for our free trial you will see our email@myosrens.com addresses.


Similar Companies:
EluSys Therapeutics
The company profile also contains facebook info, phone numbers, linkedin accounts, cfo contacts, and EluSys Therapeutics email format addresses with the domain of @elusys.com. EluSys Therapeutics, a Biotech/drugs company has its main office in Pine Brook, NJ.  If you sign up for our free trial you will see our email@elusys.com addresses.
Merck & Co., Inc
This includes Merck & Co., Inc email format addresses with the @merck.com domain, contacts, phone numbers, linkedin info, cfo employees, and facebook profiles. Merck & Co., Inc is a Biotech/drugs business with its headquarters based in Kenilworth, NJ.  If you sign up for our free trial you will see our email@merck.com addresses.
Immunomedics, Inc.
Immunomedics, Inc., a business led by CEO Michael Garone, is part of the Biotech/drugs industry. Immunomedics, Inc. email  with the @immunomedics.com format, you can check their Lead411 profile. They hold their main office in Morris Plains, NJ and more data like cfo contacts and linkedin data can be found within our profiles.  If you sign up for our free trial you will see our email@immunomedics.com addresses.




Company Directory > MYOS RENS Technology Inc.























Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft















joseph mannello - WOW.com - Web Results










AOL Search
Skip over navigation

















Search the Web



























Web





Images


Images




Reference


Reference










We Found Joseph Mannello - Searching for Joseph Mannello?



Ad
 ·
www.Spokeo.com/​Joseph Mannello



Searching for Joseph Mannello? Get Phone #,  Address, Pics & More!





Social Network Search



White Pages Directory




Search Public Records



Free People Search





We Found Joseph Mannello | BeenVerified.com



Ad
 ·
www.BeenVerified.com



1) Joseph Mannello's Phone 2) Address 3) Age & More. Search Free!





People Search



Search By Name



Search by Email




Best Background Check



Social Media



Get Contact Information





We Found Joseph Joseph | peoplelooker.com



Ad
 ·
www.peoplelooker.com/​Joseph Joseph



1) Joseph Joseph's Phone 2) Address 3) Age & More. Search Free!





Uncover Potential Relatives



Location History



Photos & Videos



Email Address




Web Results

Joseph Mannello: Executive Profile & Biography - Bloomberg

https://www.bloomberg.com/research/stocks/private/person.asp?...


Mr. Joseph Mannello, also Known as Joe, has been Interim Chief Executive Officer of MYOS RENS Technology Inc. since September 1, 2016. Mr. Mannello served as a ...


Top 5 Joseph Mannello profiles | LinkedIn

https://www.linkedin.com/pub/dir/Joseph/Mannello


View the profiles of professionals named Joseph Mannello on LinkedIn. There are 5 professionals named Joseph Mannello, who use LinkedIn to exchange information, ideas ...


Joseph Mannello (Greater New York City Area) on LinkedIn

https://www.linkedin.com/in/joseph-mannello-7b495915


View Joseph Mannello’s professional profile on LinkedIn. LinkedIn is the world's largest business network, helping professionals like Joseph Mannello discover ...


Joseph Mannello's Phone Number, Email, Address - Spokeo

https://www.spokeo.com/Joseph-Mannello


23 records for Joseph Mannello. Find Joseph Mannello's phone, address, and email on Spokeo, the leading online directory


Who is Joseph Mannello - (908) 766-4222 - Bernardsville ...

waatp.com/people/joseph-mannello/49721014


Who is Joseph Mannello - (908) 766-4222 - Bernardsville - NJ - waatp.com.See also Joseph Mannello: pictures, social networks profiles, videos, weblinks, at blogs, at ...


Top 4 Joseph Mannello profiles in United States | LinkedIn

https://us.linkedin.com/pub/dir/Joseph/Mannello/us-0-United-States


View the profiles of professionals named Joseph Mannello on LinkedIn. There are 4 professionals named Joseph Mannello, who use LinkedIn to exchange information, ideas ...


Joseph Mannello - 16 Public Records Found

https://www.instantcheckmate.com/people/joseph-mannello


Joseph Mannello was found 16 times in our database. Matches found in 15 cities including Morrisville, Pennsylvania, Summit, New Jersey & Maplewood, New Jersey.


MYOS RENS Technology Inc. Appoints Joseph Mannello as ...

www.marketwired.com/press-release/myos-rens-technology-inc...


September 07, 2016 12:32 ET. MYOS RENS Technology Inc. Appoints Joseph Mannello as Interim Chief Executive Officer . Company Also Announces Election of Victor Mandel ...


JOSEPH MANNELLO Arrest - Ulster County

https://jailalert.com/arrest-records/joseph-mannello-4735371.html


Arrested Person: Joseph Mannello. Arrested by: Ulster County Sheriff's Office. Arrest Date: 11/11/2015.


MYOS Appoints Joseph Mannello As Interim Chief Executive ...

https://www.biospace.com/News/myos-appoints-joseph-mannello-as...


Company Contact Joseph Mannello CEO MYOS RENS Technology Inc. Email Contact (973) 509-0444 Investor Relations Contact Michael Briola CEO Motion Communications, Inc.










We Found Joseph Mannello - Searching for Joseph Mannello?



Ad
 ·
www.Spokeo.com/​Joseph Mannello



Searching for Joseph Mannello? Get Phone #,  Address, Pics & More!





Social Network Search



White Pages Directory




Search Public Records



Free People Search





We Found Joseph Mannello | BeenVerified.com



Ad
 ·
www.BeenVerified.com



1) Joseph Mannello's Phone 2) Address 3) Age & More. Search Free!





People Search



Search By Name



Search by Email




Best Background Check



Social Media



Get Contact Information





We Found Joseph Joseph | peoplelooker.com



Ad
 ·
www.peoplelooker.com/​Joseph Joseph



1) Joseph Joseph's Phone 2) Address 3) Age & More. Search Free!





Uncover Potential Relatives



Location History



Photos & Videos



Email Address



12345Next














Search the Web

















© AOL Inc. All Rights Reserved.Privacy
 | Terms of Use
 | About our Ads
 | Preferences
 | Contact Us
 | Powered by Bing™

Part of the AOL Search Network.








